Dermatology Medical News about Pharmacoeconomic

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pharmacoeconomic Considerations in Treating Actinic Keratosis
PharmacoEconomics, 08/03/09

Neidecker MV et al. – Pharmacoeconomic research defining standards, outcomes and areas of efficiencies in the treatment of actinic keratosis is in its infancy. To move towards more comprehensive analysis, research needs to focus on updating epidemiological data, evolving evidence–based standards, delineating cost drivers in immunocompetent and immunocompromised populations, and on health outcomes.

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IV
Value in Health, 10/19/09 Relevance Score: 84%

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VI
Value in Health, 10/29/09 Relevance Score: 82%

The possible macroeconomic impact on the UK of an influenza pandemic
Health Economics, 10/29/09 Relevance Score: 80%

A simple cost-effective high performance liquid chromatographic assay of sulphadoxine in whole blood spotted on filter paper for field studies
Malaria Journal, 10/27/09 Relevance Score: 80%

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
Clinical Pharmacokinetics, 10/15/09 Relevance Score: 80%